News

CEO, Damien McDevitt, Named in San Diego Business Journal’s 500 Most Influential People in San Diego

by

Our CEO, Damien McDevitt, was named in the San Diego Business Journal’s 500 Most Influential People in San Diego. With over two decades of experience in life sciences, Damien is leading our mission to bring personalized, induced pluripotent stem cell treatments to patients with Parkinson’s Disease.  Read more here: https://sdbusinessjournal.pressreader.com/san-diego-business-journal/20241118/

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Present at 2023 Cell & Gene Meeting on the Mesa

by
Untitled design 3

SAN DIEGO, Oct. 9, 2023 /PRNewswire/ — Aspen Neuroscience announced today that Chief Technology Officer Kim Raineri and Chief Scientific Officer Xiaokui Zhang, Ph.D. will present at the annual Cell & Gene Meeting on the Mesa, held this week in Carlsbad, Calif. and live-streamed globally. CTO Kim Raineri will present a corporate overview of Aspen Neuroscience, highlighting its work in the development of iPSC-derived … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona

by
wpc2023 logo color scaled

SAN DIEGO, June 29, 2023 /PRNewswire/ — Next week at the upcoming World Parkinson Congress (WPC) 2023 in Barcelona, Spain, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President, Research and Development, will present preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for treatment of Parkinson’s Disease (PD). “Preclinical Safety and Efficacy of Dopamine … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Chief Scientific Officer Xiaokui Zhang Profiled in Insights Care Magazine

by
ProjectLogojpg

Our Chief Scientific Officer, Xiaokui Zhang, PhD, was profiled in the Insights Care article titled, “Xiaokui Zhang: Nurturing Healthcare Through Innovative Leadership.” The article can be found here: https://insightscare.com/xiaokui-zhang-nurturing-healthcare-through-innovative-leadership/

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Featured in the Wall Street Journal

by
WSJ

Aspen Neuroscience is excited to be featured, and very proud of the progress we’ve made to advance the science. Thank you to the Wall Street Journal for providing focus to iPSCs. The article can be found here: https://www.wsj.com/articles/stem-cells-parkinsons-disease-heart-failure-60e9e21f?st=noc464icymdkvso&reflink=desktopwebshare_permalink

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

CEO Damien McDevitt, PhD, Featured in Biocom’s Article, “A Look at the Year Ahead for Life Sciences.”

by
iStock 1416621458 scaled e1674074751412 1

Aspen Neuroscience’s CEO, Damien McDevitt, PhD, was featured in Biocom California’s article, “A Look at the Year Ahead for Life Sciences.” Damien states, “The lack of treatment options for patients with neurodegenerative diseases remains a significant unmet medical need, especially options that slow down or cure the underlying disease pathogenesis. The development of cell therapy … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Kim Raineri and Andrés Bratt-Leal, PhD, presented at Phacilitate Advanced Therapies Week

by
Andrés Bratt Leal, PhD

Aspen Neuroscience’s Co-Founder and Senior Vice President of Research and Development, Andrés Bratt-Leal, PhD, and Chief Technology Officer, Kim Raineri, presented at the Advanced Therapies Week session, “Cell and Gene Therapy for Neurological Indications” on Friday, January 20th.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Selected as a Finalist for the Phacilitate Biotech Innovation Award

by
Untitled design 6

Aspen Neuroscience was selected as a finalist for the Biotech Innovation Award at the Advanced Therapies Awards at Phacilitate Advanced Therapies Week.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience’s Thorsten Gorba, PhD, and Xiaokui Zhang, PhD, Presented at the iPSC-Derived Cell Therapies Summit

by
Xiaokui and Thorsten

Aspen Neuroscience’s Chief Scientific Officer Xioakui Zhang, PhD, served as a panel member at the annual iPSC-Derived Cell Therapies Summit in Boston during “Industry Leaders’ Fireside Chat: Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies & Determining Future Outlook & Developments,” on Tuesday, December 6th. She reflected on current learnings from therapeutics development to drive … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience will Present at the Annual iPSC-Derived Cell Therapies Summit

by
IPSC Summit Logo 2022

We are looking forward to presenting this week at the annual iPSC-Derived Cell Therapies Summit in Boston. Xiaokui Zhang, PhD, Aspen’s Chief Scientific officer will serve as a panel member on Tuesday, December 6th at 8:30 a.m. during “Industry Leaders’ Fireside Chat: Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies & Determining Future … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved